Hims & Hers Stock Seeks Stability After Steep Decline

Hims & Hers reports Q4 earnings amid a 50% stock plunge. Key focus is on the company's plan to recover from GLP-1 setbacks and justify its $1.15B acquisition.

All attention is on Hims & Hers Health, Inc. today as the company prepares to release its quarterly earnings after the market closes. This follows a period of intense pressure on Wall Street, with the company's shares having plummeted by nearly 50% over the past month. The critical question for investors is whether these results can signal a reversal of fortune or if further setbacks lie ahead.

Regulatory and Competitive Headwinds Mount

The stock's recent crash to a new 52-week low of €13.15 was triggered by significant challenges in its promising weight-loss medication segment. In early February, Hims & Hers announced it would halt sales of a recently launched compounded oral semaglutide tablet. This decision came in response to warnings from the U.S. Food and Drug Administration (FDA) and a patent infringement lawsuit filed by pharmaceutical giant Novo Nordisk.

This development strikes at the core of the growth narrative that had attracted many shareholders, directly explaining the severe loss of investor confidence witnessed in recent weeks. The market for GLP-1 weight reduction drugs, once a major opportunity, has become a source of substantial operational risk.

A Billion-Dollar Strategic Pivot

Confronted with these obstacles, the company's management has unveiled an aggressive expansion plan. Hims & Hers intends to acquire the Australian digital health provider Eucalyptus in a deal valued at up to $1.15 billion. An initial payment of approximately $240 million is expected upon closure.

Analysts interpret this move as a strategic attempt to reduce reliance on the U.S. market and unlock new revenue streams. The acquisition of Eucalyptus is projected to deliver not only an established international customer base but also contribute meaningful annual sales. Integration of the businesses is currently scheduled for mid-2026.

Quarterly Expectations and the Path Forward

For the fourth quarter of 2025, which concluded recently, company guidance had projected revenue in the range of $605 million to $625 million. Adjusted EBITDA is anticipated to land between $55 million and $65 million. These targets follow a strong third-quarter performance that saw growth of 49%, setting a high bar for the latest results.

The earnings report will be published after U.S. markets close. However, the subsequent conference call with management will likely be more crucial for determining if the equity has found a bottom. Executives will need to provide a clear roadmap for offsetting the lost revenue from the GLP-1 business and articulate the specific, near-term synergies expected from the costly Eucalyptus acquisition. The market's verdict will hinge on the credibility of this recovery plan.